484.86 USD
+8.5 (+1.78%)
484.86 USD
0 (0%)
Overall UTHR gets a fundamental rating of 7 out of 10. We evaluated UTHR against 531 industry peers in the Biotechnology industry. UTHR scores excellent points on both the profitability and health parts. This is a solid base for a good stock. UTHR has a decent growth rate and is not valued too expensively. These ratings would make UTHR suitable for quality investing!
1. Profitability
1.1 Basic Checks
UTHR had positive earnings in the past year.
In the past year UTHR had a positive cash flow from operations.
In the past 5 years UTHR has always been profitable.
UTHR had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of UTHR (17.30%) is better than 95.86% of its industry peers.
UTHR has a better Return On Equity (19.30%) than 95.67% of its industry peers.
With an excellent Return On Invested Capital value of 17.33%, UTHR belongs to the best of the industry, outperforming 96.99% of the companies in the same industry.
UTHR had an Average Return On Invested Capital over the past 3 years of 14.96%. This is below the industry average of 18.22%.
The last Return On Invested Capital (17.33%) for UTHR is above the 3 year average (14.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROIC | 17.33% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
1.3 Margins
The Profit Margin of UTHR (40.65%) is better than 96.99% of its industry peers.
In the last couple of years the Profit Margin of UTHR has grown nicely.
Looking at the Operating Margin, with a value of 48.65%, UTHR belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
In the last couple of years the Operating Margin of UTHR has grown nicely.
UTHR has a better Gross Margin (88.59%) than 90.40% of its industry peers.
In the last couple of years the Gross Margin of UTHR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% |
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
UTHR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
UTHR has less shares outstanding than it did 1 year ago.
UTHR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, UTHR has an improved debt to assets ratio.
2.2 Solvency
UTHR has an Altman-Z score of 19.32. This indicates that UTHR is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 19.32, UTHR belongs to the top of the industry, outperforming 88.32% of the companies in the same industry.
UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 19.32 |
ROIC/WACC1.98
WACC8.76%
2.3 Liquidity
A Current Ratio of 6.40 indicates that UTHR has no problem at all paying its short term obligations.
UTHR's Current ratio of 6.40 is fine compared to the rest of the industry. UTHR outperforms 65.35% of its industry peers.
UTHR has a Quick Ratio of 6.07. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of UTHR (6.07) is better than 64.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 15.90% over the past year.
The Earnings Per Share has been growing by 16.88% on average over the past years. This is quite good.
The Revenue has grown by 13.50% in the past year. This is quite good.
UTHR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.71% yearly.
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
3.2 Future
Based on estimates for the next years, UTHR will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.57% on average per year.
UTHR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.21% yearly.
EPS Next Y12.23%
EPS Next 2Y9.98%
EPS Next 3Y8.48%
EPS Next 5Y11.57%
Revenue Next Year11.53%
Revenue Next 2Y8.62%
Revenue Next 3Y8.84%
Revenue Next 5Y11.21%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 18.37, the valuation of UTHR can be described as rather expensive.
Based on the Price/Earnings ratio, UTHR is valued cheaply inside the industry as 94.73% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of UTHR to the average of the S&P500 Index (26.59), we can say UTHR is valued slightly cheaper.
A Price/Forward Earnings ratio of 16.30 indicates a correct valuation of UTHR.
Based on the Price/Forward Earnings ratio, UTHR is valued cheaper than 95.67% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.80. UTHR is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.37 | ||
| Fwd PE | 16.3 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, UTHR is valued cheaper than 96.61% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, UTHR is valued cheaper than 95.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.7 | ||
| EV/EBITDA | 10.17 |
4.3 Compensation for Growth
UTHR's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
UTHR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.5
PEG (5Y)1.09
EPS Next 2Y9.98%
EPS Next 3Y8.48%
5. Dividend
5.1 Amount
UTHR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
484.86
+8.5 (+1.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.66%
Inst Owner Change-5.19%
Ins Owners1.84%
Ins Owner Change3.66%
Market Cap20.88B
Revenue(TTM)3.13B
Net Income(TTM)1.27B
Analysts80.95
Price Target520.16 (7.28%)
Short Float %3.92%
Short Ratio2.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.9%
Min EPS beat(2)-9.46%
Max EPS beat(2)-2.35%
EPS beat(4)0
Avg EPS beat(4)-4.02%
Min EPS beat(4)-9.46%
Max EPS beat(4)-0.45%
EPS beat(8)2
Avg EPS beat(8)-2.47%
EPS beat(12)5
Avg EPS beat(12)-3.15%
EPS beat(16)7
Avg EPS beat(16)-2.98%
Revenue beat(2)0
Avg Revenue beat(2)-3.23%
Min Revenue beat(2)-3.81%
Max Revenue beat(2)-2.65%
Revenue beat(4)1
Avg Revenue beat(4)-0.39%
Min Revenue beat(4)-3.81%
Max Revenue beat(4)6.71%
Revenue beat(8)5
Avg Revenue beat(8)1.56%
Revenue beat(12)7
Avg Revenue beat(12)1.27%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)4.11%
PT rev (3m)34.57%
EPS NQ rev (1m)-2.71%
EPS NQ rev (3m)3.25%
EPS NY rev (1m)-1.69%
EPS NY rev (3m)-0.35%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)1.69%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.37 | ||
| Fwd PE | 16.3 | ||
| P/S | 6.67 | ||
| P/FCF | 18.7 | ||
| P/OCF | 13.42 | ||
| P/B | 3.17 | ||
| P/tB | 3.23 | ||
| EV/EBITDA | 10.17 |
EPS(TTM)26.39
EY5.44%
EPS(NY)29.75
Fwd EY6.14%
FCF(TTM)25.93
FCFY5.35%
OCF(TTM)36.14
OCFY7.45%
SpS72.65
BVpS153.05
TBVpS150.34
PEG (NY)1.5
PEG (5Y)1.09
Graham Number301.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROCE | 22.37% | ||
| ROIC | 17.33% | ||
| ROICexc | 29.21% | ||
| ROICexgc | 30.07% | ||
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% | ||
| FCFM | 35.69% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
ROICexc(3y)29.18%
ROICexc(5y)24.89%
ROICexgc(3y)30.03%
ROICexgc(5y)25.71%
ROCE(3y)19.31%
ROCE(5y)17.18%
ROICexgc growth 3Y23.22%
ROICexgc growth 5Y4.92%
ROICexc growth 3Y22.46%
ROICexc growth 5Y5.97%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 533.09% | ||
| Cap/Sales | 14.06% | ||
| Interest Coverage | 81.39 | ||
| Cash Conversion | 96.99% | ||
| Profit Quality | 87.79% | ||
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 | ||
| Altman-Z | 19.32 |
F-Score8
WACC8.76%
ROIC/WACC1.98
Cap/Depr(3y)347.88%
Cap/Depr(5y)280.91%
Cap/Sales(3y)8.54%
Cap/Sales(5y)7.36%
Profit Quality(3y)85.86%
Profit Quality(5y)98.64%
High Growth Momentum
Growth
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
EPS Next Y12.23%
EPS Next 2Y9.98%
EPS Next 3Y8.48%
EPS Next 5Y11.57%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
Revenue Next Year11.53%
Revenue Next 2Y8.62%
Revenue Next 3Y8.84%
Revenue Next 5Y11.21%
EBIT growth 1Y12.9%
EBIT growth 3Y28.12%
EBIT growth 5Y17.97%
EBIT Next Year20.27%
EBIT Next 3Y4.67%
EBIT Next 5Y-4.6%
FCF growth 1Y46.07%
FCF growth 3Y31.3%
FCF growth 5YN/A
OCF growth 1Y62.87%
OCF growth 3Y30.42%
OCF growth 5YN/A
UNITED THERAPEUTICS CORP / UTHR FAQ
What is the fundamental rating for UTHR stock?
ChartMill assigns a fundamental rating of 7 / 10 to UTHR.
Can you provide the valuation status for UNITED THERAPEUTICS CORP?
ChartMill assigns a valuation rating of 6 / 10 to UNITED THERAPEUTICS CORP (UTHR). This can be considered as Fairly Valued.
What is the profitability of UTHR stock?
UNITED THERAPEUTICS CORP (UTHR) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for UTHR stock?
The Price/Earnings (PE) ratio for UNITED THERAPEUTICS CORP (UTHR) is 18.37 and the Price/Book (PB) ratio is 3.17.
What is the financial health of UNITED THERAPEUTICS CORP (UTHR) stock?
The financial health rating of UNITED THERAPEUTICS CORP (UTHR) is 9 / 10.